A Phase IV real‑world analysis examined fruquintinib safety in two under‑studied CRC populations in China: young adults (<50) and the late‑elderly (≥75). Safety events were comparable between age groups, supporting broad applicability. buff.ly/1Wpdefh #ColorectalCancer

New real‑world evidence on Utidelone (UTD1) for mBC In a multicenter retrospective study of 270 pts, UTD1, used mainly in combination regimens, showed encouraging effectiveness in heavily pretreated populations. Link: buff.ly/nayTcuy #BreastCancer #MBC #Oncology

Doublet vs triplet chemo in advanced gastric & GEJ cancer: which wins? Multi-center study (493 pts) compared mFOLFOX-6 vs mDCF. Results: Similar efficacy (ORR ~37%, PFS 6 - 7 mo, OS ~12 mo), but mFOLFOX-6 had fewer grade 3-4 hematologic toxicities. 🔗https://buff.ly/UvoGGkJ

Can carboplatin AUC10 replace cisplatin in metastatic good-risk seminoma? Updated multi-centre study (236 pts, 21 yrs) shows 5-year PFS 89%, OS 93% with carboplatin AUC10. Elevated LDH predicts worse outcomes, but survival remains comparable. 🔗 buff.ly/3bOeiMh

How deep should PSA go in mCSPC? ⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design? 🔗 buff.ly/zGZ7FfA #ProstateCancer #Oncology #mCSPC #PSA #CancerResearch

NSCLC remains the leading cause of cancer mortality. This review explores how IO is being integrated into neoadjuvant, perioperative & adjuvant settings to reduce recurrence and improve survival. 👉https://buff.ly/ZsztUQH

🔍 Study on Tissue Factor (TF) in salivary gland carcinoma (SGC)! SGC is a rare head & neck cancer with diverse molecular profiles. This study analyzed TF expression in 109 patients and its link to clinicopathological features. 👉 buff.ly/6E30XWj

🔍 Review on HCC & lenvatinib response prediction! HCC remains highly lethal, and while lenvatinib is a first-line option, not all patients benefit. This review explores biomarkers that predict response, aiming to guide personalized treatment. 👉https://buff.ly/xIRqZb2

Gut microbiome matters in lymphoma care! 🦠 It shapes responses to chemo, CAR-T, and stem cell transplant. Antibiotic use can disrupt this balance - future therapies may restore it. 🔗 Read more: buff.ly/pVU90WF #Lymphoma #Microbiome #CancerResearch

BMI and weight change ≠ survival predictors in mTNBC patients on sacituzumab govitecan. Real-world Polish data show no link to PFS, OS, or AEs. 🔗 Read more: buff.ly/kHtlvYH #BreastCancer #mTNBC #Oncology

TROP2 is almost universal in OSCC (96.5% positive; 84.1% moderate-high), while Nectin-4 appears in 38.8% - higher in HPV-positive cases. Promising ADC targets! 🔗 Read more: buff.ly/nH3QbYa #HeadNeckCancer #TargetedTherapy #Oncology

KRAS mutations matter! 🧬 In a cohort of 1667 advanced solid tumors, 28.1% had KRAS aberrations. G12D was most frequent (40.6%), and G12V/G13D linked to poor survival. 🔍 Learn more: buff.ly/Z7QSjPx #Oncology #KRAS #CancerResearch

Happy Holidays and a healthy New Year from Therapeutic Advances in Medical Oncology. Thank you to our authors, reviewers, EBMs, and readers for advancing cancer research in 2025 - we look forward to sharing more breakthroughs in 2026. #HappyNewYear #Oncology buff.ly/m1hvWDs

👵🧬 Gastric cancer is rising among elderly patients, posing unique treatment challenges. This review explores systemic therapy strategies, geriatric assessments, and emerging targeted options. Read more: buff.ly/H2tEtBs #Oncology #GastricCancer #GeriatricOncology

A multicenter study of 33 advanced EC tumors treated with ICIs reveals: MMRd/MSI‑H tumors show ~81% TLS/LA vs 17% in MMRp/MSS, with strong CD8–B cell interactions; Low stromal CD68⁺ TAM density strongly predicts ICI response (OR=11.7; AUC=0.75) 🔗 Read more: buff.ly/3GlHjtf #EndometrialCancer

Capivasertib+Fulvestrant:a new targeted approach for HR⁺, HER2‑low/negative aBC, esp with PI3K/AKT/PTEN pathway alterations. Backed by FAKTION and Capitello 291, this combo shows strong efficacy and manageable safety. FDA approved 2023; NICE followed 2025. 🔗 Read more: buff.ly/yfdhSNi #BreastCancer

📣 All #ESMOImmuno25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO 👉 Watch on demand and stay at the forefront of oncology. #esmomeetings 🔗 https://ow.ly/7MwC50XHrLB

Gastric-type endocervical adenocarcinoma is highly aggressive with poor prognosis. Immunoscore predicts survival, while Claudin 18.2 & PD-L1 offer potential therapeutic targets. #Oncology #CancerResearch buff.ly/7K5gpdI

Menopause-related side effects are common in young women with HR+ early breast cancer on ovarian suppression + endocrine therapy. Hot flashes, night sweats, sleep issues & anxiety worsen over time, especially in women <40. Clinical care must address QoL. #BreastCancer buff.ly/6mZJSAr

ICI combos are reshaping hepatocellular carcinoma care. Phase III trials (IMbrave050, EMERALD-1, LEAP-012) show promise in resectable & embolization-eligible settings, but survival benefits remain unclear. More research is needed. #CancerResearch 🔗 Read the article: buff.ly/kbZ7ewQ

Immunotherapy is reshaping treatment for ES-SCLC. ICIs like atezolizumab & durvalumab push survival beyond 1 year. New targets & novel immune drugs may bring fresh hope. buff.ly/IksCUnY #CancerResearch #Immunotherapy

EVs-exRNA in bladder cancer: progress, challenges & future prospects for clinical application. Read more buff.ly/WX2dUSP #Oncology #PrecisionMedicine

EBV-positive gastric cancer is not one disease - it’s six. New review maps six EBVaGC subtypes and links each to targeted therapies, from immune checkpoint inhibitors to lytic‑induction and PI3K/Akt strategies. Read the full review buff.ly/e6lgBX9 #Oncology #GastricCancer

Genetic profiling matters: MUTYH mutation-associated PanNET shows aggressive course, frequent grade progression, and poor OS. Multinational data highlight need for tailored strategies. #Oncology #PrecisionMedicine buff.ly/5Jh8NHy

Delayed addition of PD-1/PD-L1 inhibitors to chemo may improve survival in ES-SCLC patients vs early start. Median OS: 24 vs 18.8 months after PSM. #Oncology #SCLC #Immunotherapy buff.ly/TcJIvr4

Fresh evidence on IASLC residual tumor classification: Run linked to poorer survival in operable NSCLC. Full systematic review/meta-analysis: buff.ly/EoWjoVI #NSCLC #IASLC

Adding immune checkpoint inhibitors to neoadjuvant chemo improves pCR in advanced gastric cancer. Real-world evidence from a retrospective cohort study. Read more: buff.ly/xzkJ8cL #GastricCancer #Oncology

Network meta-analysis of 11 RCTs: EV+pembrolizumab ranks highest for OS, PFS & ORR in la/mUC. Safety acceptable vs chemo. Details buff.ly/Wsqr2nQ #CancerResearch #BladderCancer

Many breast cancer survivors face diminished quality of life due to estrogen deprivation. This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship

We’re proud to see our Associate Editor, Prof. Nadia Harbeck, contributing to the upcoming #ESMOYOC YO4YO HowTo session on career crossroads in oncology. Don’t miss it! 📅 25 Nov, 15:00 CET. #YoungOncologists

🔬 CDK4/6 inhibitors have transformed HR+ MBC care - but resistance is a growing challenge. This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology

Kicking off #SIBCS2025 in Shanghai! Proud to represent Sage Publishing as Editor of Therapeutic Advances in Medical Oncology and Co-Editor of Clinical Medicine Insights: Oncology + Rare Tumors. Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch

🔬 New insights into HER2-low TNBC: • 47.7% of Asian TNBC patients classified as HER2-low • Distinct genomic profile (↓ BRCA1, ↑ PIK3CA) • No difference in survival outcomes vs HER2-zero Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch

Could the clock be a treatment factor? This retrospective study of 248 patients with mGC found better survival outcomes when nivolumab was infused before mid-afternoon. Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o

🧬 Immunotherapy has transformed cancer care-but #prostatecancer remains resistant. This review explores why traditional approaches fall short and highlights emerging strategies like: Checkpoint inhibitors; T-cell engagers; CAR-T cells buff.ly/OV5DpZ2 #ProstateCancer #Immunotherapy #Oncology #CAR_T

🏠Can indoor radon affect lung cancer mutations? The RADON EUROPE study shows a link between high radon levels (>400 Bq/m³) and ALK rearrangements in NSCLC across 21 European countries.📍 This emphasizes the need for studying environmental impacts on cancer genomics. buff.ly/C3ktYC5 #LungCancer #NSCLC

📢 Study on advanced #PancreaticCancer treatment reveals key survival factors: Only 8.3% of 204 patients lived beyond 2 years. ✅ Longer survival linked to good physical function (PS 0), low CRP & CA 19-9, high albumin, and peritoneal metastasis without fluid buildup.

📢 Call for Papers! Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt 🗓️ Join the conversation on cancer care for older adults. #GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing

Adding anti-angiogenesis therapy to PD-1/PD-L1 + chemo improves PFS and ORR in ES-SCLC, especially in patients under 65. No OS benefit overall. Safety comparable. 🔗 buff.ly/tMshYDZ #LungCancer #CheckpointInhibitors #MetaAnalysis

PD-1/PD-L1 inhibitors show promise in HBV-related hepatocellular carcinoma. Patients with low HBV DNA and early qHBsAg response had longer survival. Viral biomarkers could shape future immunotherapy strategies. buff.ly/ciwROOE #LiverCancer #HBV #CheckpointInhibitors

Pregnancy after BC is not only possible - it’s often safe. But young survivors need tailored, multidisciplinary support to navigate fertility, treatment, and long-term health. More research is needed on novel agents like CDK4/6 and PARP inhibitors. buff.ly/l10yF3b #OncoFertility #BreastCancer

🧠 New real-world data on HER2-positive MIBC suggests limited benefit from adjuvant chemo or targeted therapy. With a 5-year DFS of 95.1%, this @tamedoncol.bsky.social study raises important questions about treatment necessity 🔗 buff.ly/HBeagpd #BreastCancer #HER2 #OncologyResearch

Precision matters. A new @tamedoncol.bsky.social review dives into the evolving landscape of non-clear cell RCC, emphasizing molecular profiling, novel targets, and the 2022 WHO reclassification. Read more: buff.ly/5jyCunC #RenalCellCarcinoma #nccRCC #TargetedTherapy

🚀 The future of #GastricCancer therapy may lie beyond traditional oncogenic targets. Explore how Claudin18.2, Nectin-4, and Caprin-1 are opening new doors for precision oncology in this @tamedoncol.bsky.social review. 🔗 journals.sagepub.com/doi/full/10.... #OncologyResearch #ESMO25 #CancerTherapy

🎉 Honoring excellence in oncology! Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award. A true leader in advancing cancer care and inspiring the next generation of researchers. #WomenInSTEM #OncologyLeadership #lungcancer

In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance. 🔗 journals.sagepub.com/doi/epdf/10....

In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit journals.sagepub.com/doi/epdf/10....

In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors. 🔗 journals.sagepub.com/doi/epdf/10.... #HER2 #SalivaryCancer #Oncology

In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches. Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy. 🔗 journals.sagepub.com/doi/epdf/10....

In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice. 🔗 journals.sagepub.com/doi/epdf/10....